2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13B.06 Efficacy and Safety Analysis of Atezolizumab Continuation Beyond Progression in Extensive Small Cell Lung Cancer(ES-SCLC)

EP.13B.06 Efficacy and Safety Analysis of Atezolizumab Continuation Beyond Progression in Extensive Small Cell Lung Cancer(ES-SCLC)

Back to course

Pdf Summary

The study focuses on evaluating the efficacy and safety of continuing atezolizumab therapy beyond progression in patients with extensive-stage small cell lung cancer (ES-SCLC). Despite the initial breakthroughs using immune checkpoint inhibitors (ICIs) in treating ES-SCLC, resistance often develops. This research investigates whether continuing atezolizumab therapy after disease progression can offer benefits, as seen in other cancers.<br /><br />In this multicenter study, 28 patients received atezolizumab as a second-line treatment following progression after first-line chemo-immunotherapy. The study measured median overall survival (mOS) and median progression-free survival (mPFS), with results showing a median PFS of 4.07 months and an overall median survival of 18.87 months. There were notable subgroup differences; patients with a longer first-line progression-free interval (1L-PFS) exceeding six months (LTR group) achieved a longer median overall survival (19.98 months) than those in the short-term responder (STR) group. Those with a deeper percentage response (DpR) of 29% or more also showed enhanced overall survival (21.84 months).<br /><br />Regarding safety, common adverse events included respiratory issues such as cough, dyspnea, and pneumonitis, each affecting 35.7% of patients. Thyroiditis was the most frequently reported immune-related adverse event, affecting 17.9% of patients. <br /><br />The study concludes that continuing atezolizumab therapy post-progression shows promising efficacy with manageable safety in ES-SCLC patients, especially those who responded well to initial treatments. It highlights the potential for optimized ICI continuation strategies in treating ES-SCLC. Funding for the study was provided by the CQMU Program for Youth Innovation in Future Medicine, the China Postdoctoral Science Foundation, and Chongqing's special funding for postdoctoral research.

Asset Subtitle

Yuan Peng

Meta Tag

Speaker Yuan Peng

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

atezolizumab

extensive-stage small cell lung cancer

immune checkpoint inhibitors

second-line treatment

median overall survival

progression-free survival

adverse events

immune-related adverse events

ICI continuation strategies

CQMU Program for Youth Innovation